Sign in →

Test Code AMIO Amiodarone, Serum

Reporting Name

Amiodarone, S

Useful For

Monitoring amiodarone therapy, especially when amiodarone is coadministered with other drugs that may interact

 

Evaluating possible amiodarone toxicity

 

Assessing patient compliance

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1.5 mL

Collection Instructions:

1. Draw blood no sooner than 12 hours (trough value) after last dose or immediately before next scheduled dose.

2. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  24 hours

Reference Values

AMIODARONE

Trough Value

0.5-2.0 mcg/mL: Therapeutic concentration

>2.5 mcg/mL: Toxic concentration

 

DESETHYLAMIODARONE

No therapeutic range established for desethylamiodarone; activity and serum concentration are similar to parent drug.

Day(s) Performed

Monday through Friday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80151

LOINC Code Information

Test ID Test Order Name Order LOINC Value
AMIO Amiodarone, S 55152-3

 

Result ID Test Result Name Result LOINC Value
9247 Amiodarone, S 3330-8
2485 Desethylamiodarone 6774-4

Interpretation

Clinical effects generally require serum concentrations above 0.5 mcg/mL.

 

Increased risk of toxicity is associated with amiodarone concentrations above 2.5 mcg/mL.

 

Although therapeutic and toxic ranges are based only on the parent drug, the active metabolite N-desethylamiodarone should be present in similar concentrations to amiodarone.

Clinical Reference

1. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250-1259

2. Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46(12):985-996

3. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol. 2001;52 Suppl1(Suppl 1):21S-34S

4. Milone MC, Shaw LM. Therapeutic drugs and their management. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:420-453

Report Available

2 to 5 days

Method Name

Liquid Chromatography Mass Spectrometry (LC-MS/MS)

Forms

If not ordering electronically, complete, print, and send a one of the following with the specimen:

-Therapeutics Test Request (T831)

-Cardiovascular Test Request (T724)